Synlet

Quick links to important sections

Synlet

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synlet

What is Synlet? Defining the Drug's Identity

Property Description
Active Ingredient Acetylsalicylic acid (ASA)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID), Antiplatelet Agent
Common Form Oral tablets, capsules
General Purpose Relieves pain and fever; inhibits blood clotting
Origin Synthetic (Salicylate derivative)

What is Synlet and Its Defining Composition?

Synlet is a medicinal preparation whose sole active ingredient is Acetylsalicylic acid (ASA), also widely recognized as Aspirin. This substance is a synthetic compound derived from the salicylate family. The product is a single-ingredient (monocomponent) medication, containing only Acetylsalicylic acid and necessary excipients. The Synlet product line often features various oral drug forms, including conventional tablets and specialized delayed-release tablets, which are designed to enhance gastric tolerance compared to standard immediate-release formulations. The availability of these forms is recognized for providing effective symptomatic relief across diverse patient needs.

Synlet’s Pharmacological Classification and Purpose

Synlet is fundamentally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification signifies its primary action to reduce swelling and provide pain relief. Furthermore, its unique mechanism secures its critical secondary classification as an Antiplatelet agent (antithrombotic). This dual functionality is well-established, as ASA is a key agent in managing symptoms and preventing certain cardiovascular events. The general purpose of this medicine is comprehensive: it provides analgesic and antipyretic benefits to relieve aches and pains and reduce fever, and provides the distinct benefit of suppressing platelet function to inhibit the formation of unwanted blood clots within the circulatory system.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Synlet?

Possible Side Effects and Safety Information

The safety profile for Synlet is defined by adverse reactions documented in official government regulatory sources, which categorize events by their frequency and the body system affected.

Adverse Reaction Groupings

Classification Examples of Reactions (Varies by Official Document)
Very Common (ge 1/10) Hot flashes, arthralgia (joint pain), headache, fatigue, nausea.
Common (ge 1/100 to <1/10) Dizziness, increased sweating, hypercholesterolemia (high cholesterol), bone pain, gastrointestinal disturbances.
Uncommon (ge 1/1,000 to <1/100) Certain cardiovascular events, specific skin reactions, or specific liver function abnormalities.

Adverse reactions are also classified by System-Organ Class (e.g., Nervous System Disorders, Musculoskeletal and Connective Tissue Disorders) to provide a structured overview of the drug's effects across the body.

Serious Adverse Reactions and Safety Limitations

Official regulatory information identifies Serious Adverse Reactions as those that are life-threatening, result in death, or require hospitalization. These specific events are detailed in the full prescribing information for healthcare providers.

Safety-related restrictions and warnings include:

  • Contraindication for Pregnancy: Synlet is contraindicated during pregnancy as it can cause fetal harm.
  • Hypersensitivity: The medicine is contraindicated in patients with known hypersensitivity or allergic reaction to the active substance or any of its excipients.
  • Bone Density and Cholesterol: Use may lead to a decrease in bone mineral density and an increase in total serum cholesterol, requiring monitoring.
  • Hepatic Impairment: Use requires caution and monitoring in patients with pre-existing severe hepatic (liver) impairment.
  • Drowsiness/Dizziness: Patients should exercise caution when operating machinery until they are aware of how the medicine affects them, due to the potential for dizziness or fatigue.

This structured safety information provides a comprehensive view of the known risks, organized according to standardized regulatory frameworks used by authorities like the FDA and EMA.

Overdose and Emergency Response

Overdose and when to seek help

The following information summarizes the officially documented descriptions of overdose for Synlet (Acetylsalicylic acid) and outlines regulatory guidance on seeking emergency medical care.

Documented Overdose Manifestations

Symptoms of toxicity often progress from initial signs known as Salicylism to severe, life-threatening events. Early manifestations documented in regulatory sources include Tinnitus (ringing in the ears), Nausea, Vomiting, Dizziness, Headache, and Hyperventilation (abnormally deep or rapid breathing). Severe outcomes formally described include Metabolic Acidosis, Seizures (Convulsions), Coma, Cerebral Edema, Pulmonary Edema, and Cardiovascular Collapse.

Required Emergency Actions

Immediate medical attention or contacting a Poison Control Center is required upon suspected overdose. Furthermore, regulatory guidelines explicitly state that emergency services must be contacted immediately if severe, life-threatening symptoms are present, such as being unconscious, experiencing a Seizure, or having difficulty breathing. Monitoring of Serum Salicylate Levels and Blood Gas is required during hospital observation.

Supportive Procedures and Antidote

No specific antidote is known for this overdose. Management procedures described in official labeling focus on supportive treatment, including Gastric Lavage, administration of Activated Charcoal, and Urinary Alkalinization to enhance elimination. Regulatory documents note that overdose may be more severe and potentially fatal in Small Children and Elderly Patients.

Therapeutic Uses of Synlet

What Synlet Treats: Main Uses and Benefits

Synlet's active ingredient may be part of symptomatic management and supports general well-being during symptomatic phases. The medication is applied in situations involving certain distressing symptoms across three main areas.

The first therapeutic area involves providing symptomatic relief from acute pain, aches, and fever, helping to address groups of symptoms that may appear suddenly, such as headaches and muscle pain. The second area focuses on supportive management for conditions involving inflammatory or irritative processes. Finally, the medication is relevant for essential management of cardiovascular risk, playing a role in managing the risk of recurrent episodes of heart attacks and ischemic strokes in appropriate patient groups.

“This medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”


Quick Fact: Relief for Symptoms related to physical discomfort

Quick Fact: Relief for Symptoms related to physical discomfort (e.g., headache, fever, muscle aches) is commonly used when short-term symptomatic assistance is needed to ease temporary functional strain.

Regulatory References

  1. NIH MedlinePlus overview on Aspirin

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

This section defines the patient population authorized to use Synlet, strictly according to the constraints established in authoritative governmental regulatory labeling (e.g., FDA, EMA). Use outside of these documented limitations is not recommended.

Eligibility Domain Official Status/Restriction
Contraindicated Populations Individuals with known hypersensitivity to the active substance or any non-active ingredient (excipient) listed in the formulation.
Age Constraints Use is not established and generally not recommended in pediatric patients (under 18 years of age) due to insufficient safety and efficacy data in this population.
Severe Organ Impairment Use is prohibited or not recommended in patients with documented severe hepatic impairment or renal impairment (e.g., end-stage renal disease or requiring dialysis), as drug exposure may be significantly altered, increasing risk.
Pregnancy/Lactation Not recommended for use during pregnancy or breastfeeding due to potential fetal/infant risk, which must be formally weighed against the treatment's necessity for the mother.

These official statements structure the eligibility profile by defining absolute exclusions (contraindications) and serious restrictions (non-recommendations) based on intrinsic patient characteristics and physiological states. A patient may only be considered an eligible candidate if they meet the adult population requirements and are free from all documented contraindications or high-risk pre-existing conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Synlet (Acetylsalicylic acid/ASA) based strictly on government regulatory information.

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Anticoagulants, Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Thrombolytics, Selective Serotonin Reuptake Inhibitors (SSRIs), Systemic Corticosteroids, Uricosuric Agents.
Specific interacting medicines Methotrexate (at ge 15 mg/ week), Ibuprofen, Valproate.
Mechanistic basis of interactions (only if stated in label) Reduced Renal Clearance (Methotrexate), Displacement from Plasma Protein Binding (Valproate), Additive Pharmacodynamic Effect (Anticoagulants, SSRIs).
Timing-based interaction rules Ibuprofen must be administered at least 2 hours after immediate-release Synlet (ASA) to prevent interference with the antiplatelet effect, as defined in labeling.

Interaction Classification and Restrictions

Classification Constraint
Contraindicated Combinations Methotrexate at doses of 15 mg/ week or greater is prohibited. High-dose Anticoagulants are also prohibited.
Exposure Modification Systemic Corticosteroids may increase salicylate clearance, potentially reducing Synlet's efficacy. Valproate can increase Synlet's plasma concentration.

The official regulatory documents define the interaction structure primarily around two categories: pharmacodynamic interactions resulting in an additive risk of bleeding with agents like anticoagulants and SSRIs, and pharmacokinetic-type interactions that modify exposure or clearance of either Synlet or the co-administered drug, such as with corticosteroids or Valproate.

Mechanism of Action

Synlet (Acetylsalicylic acid or ASA) is distinguished by its unique capacity to irreversibly inhibit the Cyclooxygenase (COX) enzymes, which are central to the synthesis of specific eicosanoids that mediate physiological processes. Its mechanism operates across multiple systems, targeting the molecular steps that initiate and perpetuate these processes.

The primary action involves the permanent deactivation of the COX-1 enzyme found in platelets. By acting as an acetylating agent, Synlet blocks the synthesis of Thromboxane A2 ( TXA2), the critical mediator for platelet aggregation. This irreversible blockade sustains the suppression of platelet function for the lifespan of the platelet, modulating the physiological cascade that produces platelet aggregation.

Concurrently, the mechanism involves blocking both COX-1 and COX-2 enzymes, which halts the production of Prostaglandin E2 ( PGE2) peripherally and centrally. The reduction of PGE2 in the hypothalamus allows the central thermoregulatory set-point to return to normal, permitting the body’s set-point to initiate heat dissipation processes. The reduction of peripheral PGE2 decreases the sensitization of nociceptors and promotes the production of anti-inflammatory mediators. This antiplatelet action is biologically constrained by continuous platelet turnover and can be limited by competitive drug interaction, where certain reversible NSAIDs temporarily occupy the COX-1 active site, blocking the necessary permanent acetylation.

Dosage and Administration Information

How Synlet is Used: Official Administration Guidelines

Synlet (Acetylsalicylic acid) administration follows distinct, label-based protocols depending on the intended use, which determines the required dose and frequency. The medicine is primarily taken via the oral route, though rectal and specialist intravenous administration are approved for specific contexts.

Dosing and Frequency

Official dosing is stratified by purpose. For long-term antiplatelet maintenance, the standard regimen is a low dose of 75 mg to 162.5 mg once daily. Conversely, for analgesic and antipyretic use, a higher dose of 325 mg to 650 mg is typically taken as needed, with a maximum limit of 3,900 mg (3.9 grams) in a 24-hour period. This intermittent use allows for dosing every 4 to 6 hours.

Administration Conditions and Handling

Oral forms should generally be taken with a full glass of water and are often advised to be taken with or immediately after food to help mitigate gastrointestinal irritation. Certain formulations, such as enteric-coated or delayed-release tablets, must be swallowed whole and must not be crushed, broken, or chewed to preserve the intended release profile.

For self-treatment of pain or fever, use should not exceed 10 days; antiplatelet use is typically a long-term, indefinite regimen. If a scheduled daily dose is missed, it should be taken when remembered, but the patient must skip the missed dose if it is almost time for the next dose, and not take a double dose. Use in children and adolescents is generally not recommended or is contraindicated without specific physician instruction.

Recent Clinical Evidence

Synlet: Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus

Research has examined Synlet in studies exploring Type 2 Diabetes Mellitus, a condition characterized by functional limitations related to how the body uses sugar. Studies were conducted over defined time intervals to monitor findings related to systemic or functional imbalance, specifically looking at outcomes related to blood sugar levels. These clinical trials, which often involve comparing Synlet to a placebo (an inactive substance), describe patterns observed in the studies related to various measures of blood sugar control.

The data show patterns related to outcomes related to blood sugar levels in the populations studied. For instance, patterns were observed in the study populations, such as changes in average blood sugar values. Research provides insight into short-term changes, but research does not determine whether an individual will respond similarly.

Evidence for use in Weight Management

Synlet was evaluated in studies exploring outcomes related to body weight in individuals who were overweight or obese, a condition marked by functional limitations. The research examined changes in body weight over defined study periods. The findings indicate patterns observed in the studies related to body weight changes during the time Synlet was monitored. Results apply only to the populations studied. Comparative evidence is lacking in some areas, and research exploring short-term symptom changes may not fully reflect long-term trends.

Long-term Studies and Follow-up

Research focusing on the long-term effects of Synlet, meaning periods extending beyond a year or two, remains an area where data are still emerging and certainty remains low. Follow-up durations were limited in many initial studies, meaning long-term outcomes are not fully established. This section summarizes what is currently known and unknown about how long outcomes related to weight or blood sugar were tracked over time. Evidence remains limited regarding long-term follow-up. Research is ongoing to better understand these extended-duration effects.

What is Still Uncertain about Synlet

The available evidence contributes to the broader evidence landscape but also highlights what is known—and what is still uncertain. Sample sizes were modest in some research, and subgroup findings are uncertain across different conditions characterized by fluctuating manifestations. This section synthesizes the main evidence gaps. Comparative evidence is lacking in some areas, and there is limited information for long-term outcomes. Findings were mixed in certain smaller studies, emphasizing that the certainty of the evidence remains low in several areas, and research is ongoing to fill these gaps.

Frequently Asked Questions (FAQ)

Common questions about Synlet (FAQ)


Q: How quickly does Synlet start to work after the first use?

Studies on Synlet’s active ingredient (Acetylsalicylic acid) indicate that the full antiplatelet effect—the ability to inhibit blood clotting—is achieved within approximately 74 minutes after taking an oral dose. This onset time can be affected by factors like the specific formulation of the medicine and individual differences.


Q: Does Synlet require any special tests or monitoring while being used?

Official information indicates that monitoring for potential changes may be required during the use of Synlet. This includes tracking potential decreases in bone mineral density or increases in total serum cholesterol. Furthermore, if a patient has pre-existing severe hepatic (liver) impairment, caution and careful monitoring are required.


Q: Is it normal to have [Non-Specific Symptom, e.g., dry mouth] when starting Synlet?

Official regulatory documents list all known adverse events associated with Synlet, categorizing them by how frequently they are reported by patients. If a new symptom is experienced, official documents recommend referring to the full prescribing information to review the complete safety profile for reported events.


Q: Do Synlet's side effects usually go away over time?

Regulatory documentation suggests that adverse events observed during treatment are generally described as mild in nature and reversible. However, official sources do not guarantee a set resolution time for every specific reaction, and the resolution time frame is not consistently established.


Q: What is the risk of dependence or addiction with Synlet?

The active ingredient in Synlet is not classified as a controlled substance under the U.S. Controlled Substances Act. This classification is given to drugs that are typically associated with euphoric effects or have a high potential for abuse. Synlet's mechanism of action does not correspond to these types of effects.


Q: Are there any foods or drinks that should be avoided when taking Synlet?

Regulatory documents do not list specific food groups that are generally prohibited while using Synlet. The official information does note that taking the medicine with food is generally recommended to help mitigate the possibility of gastrointestinal (stomach) irritation.


Q: Is there a concern about Synlet interacting with herbal supplements?

Official documents describe the requirement for patients to provide their healthcare provider with all other medications they are using, including vitamins and herbs. This allows the professional to fully assess any potential interactions before Synlet is started.


Q: Can Synlet affect the effectiveness of birth control pills?

Official drug interaction checkers and regulatory reviews for Synlet's active ingredient, when assessed against certain hormonal contraceptives, have not found a direct interaction that affects the effectiveness of the birth control pill itself.


Q: Does alcohol pose a risk when using Synlet?

Official labeling contains an Alcohol Warning advising that daily consumption of three or more alcoholic drinks can increase the risk of stomach bleeding when the medicine is being used.


Q: Is Synlet safe for people with a history of liver issues?

Official information states that use requires caution and monitoring in patients with pre-existing severe hepatic (liver) impairment. The official regulatory documents do not specifically define the status for a history of liver issues or those with non-severe impairment.


Q: Can Synlet be used by people with kidney problems?

Official labeling advises that use is prohibited or not recommended in patients with documented severe renal (kidney) impairment, such as those with end-stage renal disease or requiring dialysis. The official information does not define the appropriate status for non-severe kidney issues.


Q: Can older adults use Synlet safely?

Official evidence suggests that use in the geriatric population, typically defined as age 60 and over, is associated with differences in safety and effectiveness. Regulatory agencies require that caution and monitoring be employed in this population, as older patients may be more susceptible to adverse reactions.


Q: What does the research say about Synlet's effectiveness after one year?

Official regulatory reviews note that research focusing on long-term effects, defined as periods extending beyond a year or two, is still an area where data are emerging. This means that the long-term outcomes and effectiveness are not fully established in the research.


Q: What is the general level of evidence supporting Synlet's use?

Research indicates that the certainty of the evidence remains low in several areas, including long-term outcomes. Official reviews also note that comparative evidence (studies comparing Synlet to other treatments) is lacking in some areas of research.


Q: How long do the effects of a Synlet dose typically last?

Due to its mechanism of irreversible action, the antiplatelet effect of Synlet's active ingredient persists for the entire lifespan of the affected platelets. This duration is typically estimated to be 7 to 10 days.


Q: Does Synlet cause weight gain?

Official research reports have examined outcomes related to body weight and indicate that patterns of weight changes were observed in the study populations. However, the official label does not state that the drug causes weight gain.


Q: Is it possible to develop a tolerance to Synlet over time?

Tolerance has been studied in specific clinical contexts, such as the desensitization of patients with acetylsalicylic acid-sensitive asthma. However, this topic does not have a general, defined statement in regulatory documents related to the development of physical dependence.


Q: Can Synlet affect your mood or mental clarity?

The official safety profile lists central nervous system (CNS) effects such as headache, dizziness, and fatigue as common or very common occurrences. More rare events, such as confusion or abnormally excited mood, have also been documented in the full prescribing information for healthcare providers.


Q: Why is Synlet not prescribed for everyone with the condition it treats?

Official regulatory documents define specific factors that make Synlet prohibited or not recommended for certain patients. These contraindications include known hypersensitivity (severe allergic reaction), severe organ impairment (liver or kidney), and use during pregnancy and breastfeeding.


Q: Is Synlet a controlled substance?

The active ingredient in Synlet is not classified as a controlled substance under the U.S. Controlled Substances Act. This classification is reserved for drugs with a defined potential for abuse or dependence.


Q: Is there a generic version of Synlet available?

The active ingredient in Synlet, Acetylsalicylic acid (ASA), is widely available globally in numerous generic and multi-source formulations, in addition to brand-name products.


Q: Is Synlet a stimulant?

Synlet is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Antiplatelet Agent. Its primary mechanism of action and effects do not correspond to the functions of a stimulant.


Q: Does Synlet cause changes in appetite?

While changes to appetite are not typically listed as a primary side effect, the official profile does commonly list nausea and gastrointestinal disturbances. These events can sometimes be associated with a change in a patient's appetite.


Q: Do studies show Synlet's benefit is consistent across all types of the condition it treats?

Official research notes that subgroup findings are uncertain across different conditions characterized by fluctuating manifestations. This indicates that the consistency of the drug’s benefit across all subtypes of the treated condition may not be fully established.


Q: Can Synlet affect my sleep patterns?

Adverse effects related to the central nervous system have been documented, such as drowsiness, restlessness, and irritability. These types of events may have an effect on a patient's overall sleep patterns.

How should Synlet be stored and disposed of?

How to Store and Dispose of Synlet?

The storage and disposal of Synlet must adhere strictly to regulatory requirements to ensure product stability and safety.

Storage Conditions

Synlet must be stored at controlled room temperature, typically below 25 C (77 F). It is mandatory to keep the medication protected from light and moisture; therefore, store it in its original, tightly closed container and avoid environments with excessive humidity or heat, such as bathrooms. Do not freeze the tablets. To maintain safety, Synlet must be kept out of the sight and reach of children.

Disposal Instructions

Official disposal guidance recommends utilizing a drug take-back program as the preferred method for discarding unused or expired Synlet. If a take-back program is not available, the medicine can be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container before being thrown into household trash. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Synlet found in:

A-Z Index: